DETECTION OF ANTI-HEPATITIS C VIRUS-ANTIBODIES IN PATIENTS UNDERGOINGDIALYSIS BY UTILIZING A HEPATITIS-C VIRUS-3.0 ASSAY - CORRELATION WITH HEPATITIS-C VIRUS-RNA
M. Demedina et al., DETECTION OF ANTI-HEPATITIS C VIRUS-ANTIBODIES IN PATIENTS UNDERGOINGDIALYSIS BY UTILIZING A HEPATITIS-C VIRUS-3.0 ASSAY - CORRELATION WITH HEPATITIS-C VIRUS-RNA, The Journal of laboratory and clinical medicine, 132(1), 1998, pp. 73-75
Citations number
12
Categorie Soggetti
Medicine, General & Internal","Medicine, Research & Experimental","Medical Laboratory Technology
Hepatitis C virus (HCV) infection is endemic in long-term dialysis uni
ts. We assessed the performance of a recently developed HCV 3.0 assay
for the detection of HCV antibodies in patients undergoing dialysis, T
he study evaluated 128 patients undergoing long-term maintenance hemod
ialysis. Anti-HCV was detected by 2.0 and 3.0 enzyme immunoassay (EIA)
. Results were confirmed with recombinant immunoblot assays (RIBA(TM)
2.0 and RIBA(TM) 3.0). HCV RNA was detected by using reverse transcrip
tase-polymerase chain reaction (RT-PCR). Thirty-two patients (25%) wer
e HCV EIA 2.0 positive. Of these, 1 was RIBA(TM) 2.0 negative (PCR pos
itive), 3 were indeterminate (3 PCR positive), and 28 were positive (2
3 PCR positive). Thirty-five (27%) were HCV EIA 3.0 positive. One was
RIBA(TM) 3.0 negative (PCR positive), 1 was indeterminate (c33c, PCR p
ositive), and 33 were positive (27 PCR positive) by RIBA(TM) 3.0. Thus
only 1 PCR-positive patient was negative with RIBA(TM) 2.0 and 3.0 as
says. Two of the 3 RIBA(TM) 2.0 indeterminate samples were positive wi
th RIBA(TM) 3.0. One remained indeterminate but was HCV RNA positive.
In summary, HCV 3.0 EIA detected 4 additional viremic patients but was
positive in 6 PCR-negative subjects. A high correlation of the presen
ce of antibody to c33c with HCV RNA (28 of 34, 82%) was found, and it
was found in all anti-HCV positive samples and in 1 indeterminate samp
le. We conclude that the HCV EIA 3.0 test with the supplemental confir
matory RIBA(TM) 3.0 test may improve the sensitivity for the detection
of anti-HCV. Nevertheless, in potentially immunocompromised patients
undergoing dialysis, PCR continues to be the only reliable test for de
tecting viremia.